Clinical trial
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That…
NCT00086866 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Unknown status
Key facts
| NCT number | NCT00086866 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery |
| Official title | Randomized, Open Phase II Study of Immunization With the Recombinant MAGE-3 Protein Combined With Adjuvant AS02B or AS15 in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | D1/3-MAGE-3-His fusion protein, SB-AS02B adjuvant, SB-AS15 adjuvant |
| Enrollment | 165 |
| Start date | May 1, 2004 |
| Primary completion | Jan 1, 2007 |
| First posted | Jul 12, 2004 |
| Last update posted | Feb 10, 2015 |
| Countries | Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: